Humacyte announces allowance of U.S. patent for bioengineered esophagus

Humacyte (HUMA) announced the allowance of a U.S. Patent covering the composition of a bioengineered esophagus that can be produced using the Company’s proprietary regenerative tissue engineering platform. The patent, titled “Tubular Prostheses,” provides protection into 2041 of key structural and mechanical attributes for its designed use as an esophageal replacement including size, strength, and methods of production. Humacyte’s Tubular Prostheses patent family encompasses composition and methods claims for advanced tissue constructs intended to replace damaged airways, upper digestive, and urinary tracts in patients.